CRMD
CorMedix Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.43
−0.47%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 462.2M | 311.7M | 43.5M | — | 65.4K |
| Cost of Revenue | 79.6M | 36.0M | 3.2M | 205.6K | 3.7K |
| Gross Profit | 382.6M | 275.7M | 40.3M | (205.6K) | 61.7K |
| Operating Expenses | |||||
| R&D Expense | 27.6M | 19.3M | 3.9M | 13.2M | 10.7M |
| SG&A Expense | 138.0M | 30.2M | 58.7M | 35.8M | 20.0M |
| General & Admin Expense | 85.8M | 68.2M | 30.0M | 17.7M | — |
| Selling & Marketing Expense | 52.2M | (38.1M) | 28.7M | 18.1M | — |
| Other Expenses | — | 76.1M | — | — | — |
| Total Operating Expenses | 165.6M | 125.6M | 62.6M | 48.8M | 30.7M |
| Cost and Expenses | 245.2M | 161.6M | 65.8M | 49.0M | 30.7M |
| Operating Income (EBIT) | 217.0M | 150.1M | (22.4M) | (49.0M) | (30.6M) |
| Non-Operating | |||||
| Interest Income | 2.5M | 3.8M | 2.6M | 2.7M | 326.0K |
| Interest Expense | 2.8M | 2.8M | 36.4K | 34.3K | 26.5K |
| Net Interest Income | (315.1K) | 1.1M | 2.5M | 2.6M | 299.5K |
| Other Non-Op Income/Expense | (13.6M) | (125.0K) | 3.0M | 2.6M | 336.6K |
| Non-Operating Income (excl Interest) | 2.5M | (2.7M) | (3.1M) | (2.7M) | (363.2K) |
| EBT (Pre-Tax Income) | 203.4M | 150.0M | (19.3M) | (46.3M) | (30.3M) |
| Income Tax Expense | 16.2M | (13.0M) | (1.4M) | — | (585.6K) |
| Bottom Line | |||||
| Net Income | 187.2M | 163.1M | (17.9M) | (46.3M) | (29.7M) |
| Earnings from Cont. Ops | 187.2M | 163.1M | (17.9M) | (46.3M) | (29.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 186.2M | 163.1M | (17.9M) | (46.3M) | (29.7M) |
| Per Share | |||||
| Basic EPS | $2.41 | $2.25 | ($0.30) | ($0.91) | ($0.74) |
| Diluted EPS | $2.13 | $2.04 | ($0.30) | ($0.91) | ($0.74) |
| Revenue Per Share | $5.89 | $4.33 | $0.74 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 78.4M | 72.0M | 58.9M | 50.9M | 40.1M |
| Diluted Shares Outstanding | 92.5M | 80.3M | 58.9M | 50.9M | 40.3M |
| Profitability Metrics | |||||
| EBITDA | 249.6M | 167.8M | (19.0M) | (46.2M) | (30.1M) |
| D&A | 35.1M | 15.0M | 309.8K | 70.8K | 209.0K |
| EBIT | 214.5M | 152.8M | (19.3M) | (46.3M) | (30.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026